Want to see JP:4586 full AI Analyst Report?

Medrx Co., Ltd. (4586) Price & Analysis

0 Followers

4586 Stock Chart & Stats

¥113.00

¥2.00(2.50%)

At close: Jan 08 4:00 PM EST

¥113.00

¥2.00(2.50%)

Day’s Range― - ―

52-Week Range¥48.00 - ¥225.00

Previous CloseN/A

Volume596.00K

Average Volume (3M)2.57M

Market Cap

¥4.16B

Enterprise Value¥1.62B

Total Cash (Recent Filing)¥1.46B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-12.76

Shares Outstanding65,997,400

10 Day Avg. Volume1,116,360

30 Day Avg. Volume2,574,156

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)2.83

Price to Sales (P/S)45.31

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsSustained gross margins near 85–90% indicate strong unit economics from transdermal formulations and manufacturing. High gross margins create durable operating leverage potential: as revenue scales, contribution margins can absorb R&D and SG&A, improving the path to sustainable profits if fixed costs are controlled.

Conservative Balance Sheet (No Debt)A zero-debt capital structure across multiple years materially reduces solvency risk and interest burden, preserving financial optionality. This durable conservatism gives management flexibility to raise capital on better terms, fund development, or tolerate temporary cash burn without imminent default risk.

Focused Transdermal Drug Delivery ExpertiseA strategic focus on transdermal delivery creates a specialized, defensible niche with technical know-how and potential IP barriers. This product specialization supports long-term differentiation, targeted partnerships with pharma customers, and recurring manufacturing demand for prescription patch formulations.

Bears Say

Persistent Large LossesVery large recurring operating and net losses are a structural drain that erodes equity and investor flexibility. Over months to years, sustained heavy losses undermine the balance sheet, limit reinvestment ability, and force repeated financing or dilution absent a credible, durable path to operating breakeven.

Chronic Negative Cash FlowConsistent negative operating and free cash flow means the business is not self-funding and will require external financing to sustain operations. This structural cash burn increases dilution or debt needs, constrains strategic choices, and raises execution risk for product launches or commercial scale-up over the next several quarters.

Revenue Volatility And Negative ROELarge swings in revenue combined with persistently negative ROE signal unstable demand and value destruction. Volatility impairs forecasting and capital allocation, while negative returns on equity show that invested capital has not generated profits, risking further erosion if volatility and losses persist.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥48.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥4.16B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 9 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥4.02 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.02.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 65,997,400 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥4.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.063%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.